EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models (Q38863374)

7 September 2017

title

EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models (English)

1 reference

non-small-cell lung carcinoma

7 September 2017

main subject

1 reference

Niina Laurila

1

1 reference

7 September 2017

Jussi P Koivunen

series ordinal

2

1 reference

7 September 2017

publication date

17 June 2015

1 reference

7 September 2017

1 reference

7 September 2017

volume

32

1 reference

7 September 2017

issue

7

1 reference

7 September 2017

page(s)

205

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

The quest to overcome resistance to EGFR-targeted therapies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Noncovalent wild-type-sparing inhibitors of EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-015-0627-6

10.1007/S12032-015-0627-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1047955547

0 references

1 reference